Physician profile
Catherine Choi
NPI 1467689018
$3,129.50
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,386 · 2020: $647 · 2021: $917 · 2022: $38.13 · 2023: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $99.99 · Food and Beverage: $41.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $99.99 |
| Food and Beverage | $41.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $456.15 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $381.33 | 2019-2021 | |
| Lilly USA, LLC | $323.03 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $211.44 | 2019-2022 | |
| Leo Pharma INC. | $205.18 | 2019-2022 | |
| Almirall LLC | $132.51 | 2019-2021 | |
| Janssen Biotech, INC. | $127.98 | 2019-2023 | Tremfya |
| Encore Dermatology INC. | $110.88 | 2019 | |
| Epi Health, LLC | $102.44 | 2019-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $92.65 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $91.84 | 2019-2021 | |
| Pfizer INC. | $80.13 | 2019-2021 | |
| Glenmark Therapeutics INC. | $77.00 | 2019 | |
| Coherus Oncology, INC. | $74.92 | 2021 | |
| Galderma Laboratories, L.P. | $69.21 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $57.84 | 2019-2021 | |
| Celgene Corporation | $56.29 | 2019 | |
| Ucb, INC. | $54.61 | 2021 | |
| Prugen, INC. Pharmaceuticals | $54.56 | 2019-2020 | |
| Amgen INC. | $52.93 | 2021 | |
| Boston Scientific Corporation | $41.26 | 2023 | Exalt Model D, Resolution 360 Clip, Spyglass |
| Journey Medical Corporation | $33.59 | 2019-2020 | |
| Sandoz INC. | $31.20 | 2020 | |
| Vyne Pharmaceuticals INC. | $29.05 | 2021 | |
| Dermira, INC. | $28.13 | 2020 | |
| Merck Sharp & Dohme LLC | $26.65 | 2019 | |
| Genzyme Corporation | $26.39 | 2019-2021 | |
| Dusa Pharmaceuticals, INC. | $16.78 | 2019 | |
| Nabriva Therapeutics, Plc | $15.46 | 2020 | |
| Mylan Pharmaceuticals INC. | $14.63 | 2019 | |
| Dermavant Sciences, INC. | $14.00 | 2022 | |
| Mayne Pharma Commercial LLC | $13.35 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $13.11 | 2019 | |
| Mission Pharmacal Company | $12.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Choi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.